Back to Results

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for neurodegenerative diseases and endocrine disorders in the United States. Its pipeline includes avexitide, an investigational GLP-1 receptor antagonist being studied in phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism. The company is also advancing AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol, in phase 2 development for wolfram syndrome and in phase 2b/3 testing for progressive supranuclear palsy. Additional programs include AMX0114 for amyotrophic lateral sclerosis, along with longer-acting and other GLP-1 receptor antagonist candidates aimed at post-bariatric hypoglycemia and rare diseases. Founded in 2013, Amylyx is headquartered in Cambridge, Massachusetts.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-AMLX
$17.85
-35.4% Downside
Overvalued
$42.64
54.4% Upside
Bargain
Fair
0.0%
14.5x
3.467 B
2.703 B
0.1%
87.3%
81.8
83.3%
Valuation • Fair Value

Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) Fair Value by Valuation Model

Review the available estimates for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX), including Comps Fair Value.

Primary Valuation Read

Fair Value

$17.85

Estimated downside of 35.4% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$17.85

Comparable-company valuation reference.

Analyst Price Target

$42.64

Analysts imply upside of 54.4%.

How to read these valuation models

Use the 4 available valuation references for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-161.7 M

Current operating profitability reference.

EBITDA Forecast

-172 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

81.8

Relatively strong balance-sheet zone.

FCF / Net Income

83.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) Stock Forecast & Technical Outlook

Review Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) has a Strong Buy consensus, with 11 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 11
Hold 1
Sell 0
FAQ • Fast Investor Answers

Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) Stock FAQ

Data-supported answers about Amylyx Pharmaceuticals Inc (NASDAQ-AMLX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$17.85
Estimated downside 35.4%
Valuation Rating
Overvalued
Estimated downside of 35.4%
Analyst Target
$42.64
Implied upside 54.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) is $17.85. This implies an estimated downside of 35.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 35.4% versus the current market price.

The available analyst price target for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) is $42.64. The analyst target implies estimated upside of 54.4%.

The current financial health read for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Amylyx Pharmaceuticals Inc (NASDAQ-AMLX).

The current market capitalization listed for Amylyx Pharmaceuticals Inc is 3.467 B.

The current enterprise value listed for Amylyx Pharmaceuticals Inc is 2.703 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Amylyx Pharmaceuticals Inc is NASDAQ-AMLX, and the stock is listed on NASDAQ.

Amylyx Pharmaceuticals Inc (NASDAQ-AMLX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Amylyx Pharmaceuticals Inc is 0.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Amylyx Pharmaceuticals Inc is 87.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,215.6 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 655.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.2 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 310 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 179.5 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 170.3 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 129 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 113.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 69.723 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 48.75 B
HLN NYSE HALEON PLC ADR Fair Value Undervalued Market Cap 40.368 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 38.751 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.93 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 21.789 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Undervalued Market Cap 14.59 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 11.996 B
ELAN NYSE Elanco Animal Health Fair Value Overvalued Market Cap 11.831 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 7.834 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 6.827 B